Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from a late-stage study on next-generation obesity drug, CagriSema. Top-line data from the phase III REDEFINE 2 study on Novo Nordisk’s CagriSema showed that treatment with the drug led to a weight loss of 15.

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of their value during the big market sell-off that day,

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. Let's figure out how Lilly could perform through the end of the decade, and decide whether it's still worth investing in the stock.